Primary progressive multiple sclerosis (PPMS) represents 10%–15% of all multiple sclerosis (MS) diagnoses. Information regarding socio-demographic and clinical characteristics of persons with PPMS is limited.
Objective:
To characterize persons with PPMS in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.
Methods:
We compared demographic and health-related characteristics of NARCOMS Registry participants reporting PPMS in the spring 2015 update survey with those reporting relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), with characteristics of published PPMS cohorts.
Results:
Of 8004 responders, 6774 self-reported a clinical course of PPMS, SPMS, or RRMS. The PPMS cohort (n = 632, 9.3%) reported a mean (standard deviation (SD)) age of 64.3 (8.9) years; 62.7% were female; the SPMS and RRMS cohorts were younger and had a higher proportion of females. The NARCOMS PPMS cohort differed in age, time from onset and diagnosis, and proportion of females compared to population-based and clinical trial cohorts. Median (25%, 75%) number of comorbidities was 2 (1, 2) for each cohort with vascular comorbidities being most frequently reported.
Conclusion:
The NARCOMS population provides a different perspective on persons with PPMS than clinical trials. A better understanding of the characteristics of persons with PPMS may help address unmet needs in this population.
CottrellDAKremenchutzkyMRiceGPAet al. The natural history of multiple sclerosis: A geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain1999; 122(4): 641–647.
2.
KochMKingwellERieckmannPet al. The natural history of primary progressive multiple sclerosis. Neurology2009; 73(23): 1996–2002.
3.
ConfavreuxCVukusicS. Natural history of multiple sclerosis: A unifying concept. Brain2006; 129(Pt 3): 606–616.
4.
KremenchutzkyMRiceGPABaskervilleJet al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain2006; 129(Pt 3): 584–594.
5.
CottrellDA. The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain1999; 122(4): 625–639.
6.
LublinFMillerDHFreedmanMSet al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet2016; 387(10023): 1075–1084.
7.
WolinskyJSNarayanaPAO’ConnorPet al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol2007; 61(1): 14–24.
8.
HawkerKO’ConnorPFreedmanMSet al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66(4): 460–471.
9.
MontalbanXHauserSLKapposLet al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376: 209–220.
LearmonthYCMotlRWSandroffBMet al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol2013; 13(1): 37.
12.
SchwartzCEVollmerTLeeH. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology1999; 52(1): 63–70.
13.
SalterARCutterGRTyryTet al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin2010; 26(2): 493–500.
14.
HortonMRudickRAHara-CleaverCet al. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology2010; 35: 83–90.
15.
MarrieRAHorwitzRCutterGet al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology2009; 72(2): 117–124.
16.
TetteyPSimpsonSTaylorBVet al. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci2014; 347(1–2): 23–33.
17.
MocciaMLanzilloRPalladinoRet al. The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol2015; 22(8): 1176–1183.
18.
MarrieRACutterGTyryTet al. Does multiple sclerosis–associated disability differ between races?Neurology2006; 66(8): 1235–1240.
19.
TremlettHPatyDDevonshireV. The natural history of primary progressive MS in British Columbia, Canada. Neurology2005; 65(12): 1919–1923.
20.
DebouverieMLouisSPittion-VouyovitchSet al. Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol2007; 254(10): 1370–1375.
21.
HardingKEWardleMMoorePet al. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2015; 86(1): 13–19.
22.
KavaliunasAManouchehriniaADanylaite KarrenbauerVet al. Income in multiple sclerosis patients with different disease phenotypes. PLoS ONE2017; 12(1): e0169460.
23.
TunisSRStryerDBClancyCM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA2003; 290(12): 1624–1632.
24.
TreweekSZwarensteinM. Making trials matter: Pragmatic and explanatory trials and the problem of applicability. Trials2009; 10: 37–46.
CampSJStevensonVLThompsonAJet al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain2005; 128(Pt 12): 2891–2898.
27.
MarrieRAReiderNCohenJet al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler2015; 21(3): 318–331.
28.
MarrieRAPattenSBTremlettHet al. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology2016; 86(14): 1279–1286.
29.
MarrieRAHorwitzRICutterGet al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand2011; 124(2): 135–141.
30.
SalterATyryTWangGet al. Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurol Clin Pract2016; 6: 397–408.
31.
RaissiABullochAGFiestKMet al. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care2015; 17: 292–300.
32.
PoharSLJonesCAWarrenSet al. Health status and health care utilization of multiple sclerosis in Canada. Can J Neurol Sci2007; 34(2): 167–174.
33.
VazirinejadRLilleyJWardC. A health profile of adults with multiple sclerosis living in the community. Mult Scler2008; 14(8): 1099–1105.
34.
EvansCKingwellEZhuFet al. Hospital admissions and MS: Temporal trends and patient characteristics. Am J Manag Care2012; 18(11): 735–742.
35.
MarrieRACutterGTyryTet al. Validation of the NARCOMS registry: Diagnosis. Mult Scler2007; 13(6): 770–775.
